233276-35-2

Usage

Uses

Used in Organic Synthesis:
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its benzyl ether group can be selectively removed or modified, allowing for the synthesis of a wide range of compounds with diverse functional groups and properties.
Used in Pharmaceutical Development:
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol is used as a chiral building block in the development of pharmaceuticals. Its unique stereochemistry and functional groups can be utilized to create enantiomerically pure compounds with potential therapeutic applications. The chiral nature of (1s,3s)-3-(benzyloxy)cyclobutan-1-ol can be leveraged to design drugs with improved selectivity and reduced side effects.
Used in Chemical Research:
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol serves as a valuable research tool in chemical studies. Its unique structure and chirality make it an interesting target for investigating various aspects of chemical reactivity, stereoselectivity, and mechanistic insights. Researchers can use (1s,3s)-3-(benzyloxy)cyclobutan-1-ol to explore new synthetic methodologies, catalysis, and reaction pathways.
Used in Drug Discovery:
(1s,3s)-3-(benzyloxy)cyclobutan-1-ol is employed as a starting material or scaffold in drug discovery efforts. Its chiral cyclobutanol core and benzyl ether group can be further functionalized to generate novel bioactive molecules with potential therapeutic properties. (1s,3s)-3-(benzyloxy)cyclobutan-1-ol can be used to identify new lead compounds and optimize their pharmacological profiles for various diseases and conditions.

Upstream product

• 30830-27-4 3-benzyloxy cyclobutanone 
• 100-39-0 benzyl bromide 
• 35995-55-2 (2-bromo-1-bromomethylethoxymethyl)benzene 
• 100058-61-5 3-(phenylmethoxy)cyclobutan-1-ol 
• 917887-34-4 1-methylsulfinyl-1-methylthio-3-benzyloxycyclobutane 

Downstream Products

• 1262278-65-8 trans-3-(fluorocyclobutyl) benzyl ether 
• 1262278-62-5 (1s,3s)-3-(benzyloxy)cyclobutyl 4-methylbenzenesulfonate 
• 1262278-69-2 methyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-L-tyrosine 
• 1417818-85-9 methyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-D-tyrosine 

Relevant academic research and scientific papers

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO

The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPK1) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, P. falciparum, C. hominis, or C. parvum infections, using the novel inhibitors of the invention.

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

BTK inhibitor and preparation method and pharmaceutical application thereof

The invention relates to a compound as shown in a general formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic thereof, and an intermediateand a preparation method thereof, and an application of the compound in BTK related diseases such as tumors or autoimmune system diseases. B-L-K (I).

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE

Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

2 Tyrosine kinase mediated signal transduction inhibitors

Disclosed herein are compounds of Formula (), and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, X, X, X, X, X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.